Swedbank AB Has $10.89 Million Stock Position in Kenvue Inc. $KVUE

Swedbank AB reduced its stake in shares of Kenvue Inc. (NYSE:KVUE) by 6.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 520,285 shares of the company’s stock after selling 35,400 shares during the period. Swedbank AB’s holdings in Kenvue were worth $10,890,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of KVUE. Man Group plc acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $941,000. Waverly Advisors LLC raised its holdings in shares of Kenvue by 79.5% in the fourth quarter. Waverly Advisors LLC now owns 18,536 shares of the company’s stock valued at $396,000 after purchasing an additional 8,209 shares during the last quarter. Vise Technologies Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $242,000. Forum Financial Management LP raised its holdings in shares of Kenvue by 29.2% in the fourth quarter. Forum Financial Management LP now owns 22,917 shares of the company’s stock valued at $489,000 after purchasing an additional 5,174 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of Kenvue by 12.8% in the fourth quarter. Mackenzie Financial Corp now owns 444,128 shares of the company’s stock valued at $9,482,000 after purchasing an additional 50,279 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of Kenvue stock opened at $18.34 on Monday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company has a market cap of $35.20 billion, a PE ratio of 24.78, a P/E/G ratio of 2.63 and a beta of 0.83. The business has a 50 day moving average of $20.87 and a 200 day moving average of $22.04. Kenvue Inc. has a 52 week low of $17.15 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio is 112.16%.

Analyst Ratings Changes

A number of equities analysts have commented on KVUE shares. Citigroup reduced their price objective on shares of Kenvue from $22.00 to $20.00 and set a “neutral” rating for the company in a research report on Tuesday, September 16th. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, July 25th. Royal Bank Of Canada reduced their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. Finally, UBS Group reduced their price objective on shares of Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $24.04.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.